February 24, 2020
1 min read

A Safety and Efficacy Study Evaluating CTX120 in Subjects with Relapsed or Refractory Multiple Myeloma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Phase 1, single-arm, multicenter, dose-escalation and cohort-expansion study of the safety and efficacy of anti-BCMA allogeneic CRISPR/Cas9-engineered T cells (CTX120) in subjects with relapsed or refractory multiple myeloma.